| Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. | |
| | |
MedLine Citation:
|
PMID: 19370346 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The aim of our study was to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using (18)F-fluorodeoxyglucose (FDG) with IV contrast for depiction of suspected recurrent colorectal cancer and to assess the impact of PET/contrast-enhanced CT findings on clinical management compared with PET/non-contrast-enhanced CT and CT component. METHODS: One hundred seventy patients previously treated for colorectal cancer underwent PET/CT consisting of non-enhanced and contrast-enhanced CT for suspected recurrence. PET/contrast-enhanced CT, PET/non-contrast-enhanced CT and enhanced CT were interpreted by two experienced radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging and clinical follow-up for longer than 6 months. RESULTS: Patient-based analysis showed that the sensitivity, specificity and accuracy of PET/contrast-enhanced CT were 93.2 (69/74), 95.8 (92/96) and 94.7% (161/170), respectively, whereas those of PET/non-contrast-enhanced CT were 89.2 (66/74), 94.8 (91/96) and 92.4% (157/170), respectively, and those of enhanced CT were 79.7 (59/74), 93.8 (90/96) and 87.6% (149/170), respectively. Sensitivity and accuracy differed significantly among the three modalities (Cochran's Q test: p = 0.0004 and p = 0.0001, respectively).The findings of PET/contrast-enhanced CT resulted in a change of management for 64 of the 170 patients (38%) and had an effect on patient management in 12 patients (7%) diagnosed by enhanced CT alone and 4 patients (2%) diagnosed by PET/non-contrast-enhanced CT. CONCLUSION: Integrated PET/contrast-enhanced CT is an accurate modality for assessing colorectal cancer recurrence and led to changes in the subsequent appropriate therapy. |
| | |
Authors:
|
Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Masahiro Tsubaki; Masakatsu Sunagawa; Yasushi Kaji; Narufumi Suganuma; Kazuro Sugimura |
Related Documents
:
|
17114956 - Routine use of pet scans after completion of therapy in pediatric hodgkin disease resul... 12411836 - 18fdg pet versus high-dose 67ga scintigraphy for restaging and treatment follow-up of l... 9867146 - Fluorine-18-fluorodeoxyglucose pet identification of cardiac metastasis arising from ut... 21066996 - Significance of pet/ct in determining actual tnm staging for patients with various lung... 17415176 - A novel, inexpensive method of image coregistration for applications in image-guided su... 17788116 - Changing atmospheric fallout of magnetic particles recorded in recent ombrotrophic peat... |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2009-04-16 |
Journal Detail:
|
Title: European journal of nuclear medicine and molecular imaging Volume: 36 ISSN: 1619-7089 ISO Abbreviation: Eur. J. Nucl. Med. Mol. Imaging Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-11 Completed Date: 2010-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101140988 Medline TA: Eur J Nucl Med Mol Imaging Country: Germany |
Other Details:
|
Languages: eng Pagination: 1388-96 Citation Subset: IM |
Affiliation:
|
Department of Radiology, Dokkyo University School of Medicine, Mibu, Japan. kazu10041976@yahoo.co.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Colorectal Neoplasms / pathology, radiography, radionuclide imaging* Contrast Media / diagnostic use Fluorodeoxyglucose F18 / diagnostic use* Humans Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local / radiography, radionuclide imaging* Positron-Emission Tomography Radiopharmaceuticals / diagnostic use* Tomography, X-Ray Computed |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new approach to retrieve full lengths of functional genes from soil by PCR-DGGE and metagenome wal...
Next Document: Reimplantation of the resected tumour-bearing segment after recycling using liquid nitrogen for oste...